Eli Lilly announced positive Phase 3 results showing that its experimental triple-agonist drug retatrutide significantly reduced both blood sugar levels and body weight in patients with type 2 diabetes . The study met all primary and key secondary endpoints, with A1C levels falling by up to 2.0% over 40 weeks compared to placebo.

Patients receiving the highest dose achieved substantial weight loss, averaging 36.6 pounds (16.8%), with no plateau observed during the treatment period. The drug also showed improvements in cardiovascular risk markers such as cholesterol, triglycerides, and blood pressure.

The results highlight retatrutide’s potential as a next-generation therapy targeting multiple metabolic pathways, positioning it as a promising candidate in both diabetes and obesity treatment pipelines pending further clinical and regulatory progress.
PRNewswire